Skip to main content

Wound Healing

Dermatology
9
Pipeline Programs
16
Companies
16
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
4
1
0
2
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Cell Therapy
1100%
+ 20 programs with unclassified modality

Dermatology is a $292M market that is mature and consolidating, dominated by a single blockbuster approaching loss of exclusivity.

$0.292B marketMature→ Stable30 products15 companies

Key Trends

  • HUMIRA (adalimumab) dominates 88% of market spending but faces LOE in near-term, creating vulnerability
  • Novel mechanisms like aryl hydrocarbon receptor agonists gaining traction with emerging products in peak lifecycle
  • Substantial clinical trial activity (812 trials) suggests ongoing innovation pipeline despite mature market

Career Verdict

Dermatology offers stable near-term opportunities but requires strategic positioning given patent cliff risk and limited market size compared to other therapeutic areas.

AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data

Market Leaders

#1HUMIRADeclining
$258M
AbbVie·LOE_APPROACHING
#2VTAMAGrowing
$19M
Merck & Co.·PEAK13.5yr
#3ORACEADeclining
$4M
Galderma·LOE_APPROACHING1.6yr

Drug Class Breakdown

Unknown Mechanism (predominantly HUMIRA)
$258M(88%)

Patent cliff looming

Aryl Hydrocarbon Receptor Agonists
$19M(6%)

Emerging innovation

Retinoids and Derivatives
$3M(1%)

Mature segment

Other Mechanisms
$12M(4%)

Niche applications

Career Outlook

Stable

Dermatology represents a stable but narrow career path with limited growth compared to larger therapeutic areas; compensation is competitive in Commercial and Medical Affairs but R&D opportunities are scarce. HUMIRA's patent cliff creates near-term uncertainty for AbbVie but may drive restructuring and new product launches elsewhere. Market consolidation around a few large players (AbbVie, Regeneron, Merck) limits startup/biotech opportunities.

Breaking In

Enter via Commercial or Medical Affairs roles where hiring is highest; dermatology has lower scientific barrier to entry than oncology but requires strong relationship-building and market access acumen.

For Experienced Professionals

Leverage HUMIRA transition expertise or develop specialty in emerging mechanisms (retinoids, AhR agonists); consider moving to larger franchises (immunology, oncology) if seeking higher growth trajectory.

In-Demand Skills

Health Economics & Outcomes Research (HEOR)Dermatology Clinical KnowledgeSales Strategy & Account ManagementDigital Health / Telemedicine IntegrationMedical Writing for Topicals & Systemics

Best For

Regional Sales ManagerMedical Science Liaison (MSL)Product Manager (Post-Launch)Health Economics ManagerRegulatory Affairs Specialist

Hiring Landscape

$85K-$386K

Dermatology shows concentrated hiring at AbbVie (52 positions) and Regeneron (46 positions), with Commercial roles dominating (89 jobs, $188K avg salary) and Medical Affairs roles commanding premium compensation ($386K avg). Limited R&D hiring (8 positions) suggests mature drug development phase with emphasis on commercialization and market access.

173
Open Roles
3
Companies Hiring
3
Departments

Top Hiring Companies

53Growing
46Growing
14Stable

By Department

Commercial(51%)
$188K
Medical Affairs(24%)
$386K
Research & Development(5%)

Commercial and Medical Affairs roles offer strong compensation and growth, but overall job market is small; best for professionals seeking revenue-generating functions rather than discovery roles.

Competitive Landscape

16 companies ranked by most advanced pipeline stage

Bayer
BayerLEVERKUSEN, Germany
2 programs
2
DexpanthenolPhase 41 trial
DexpanthenolPhase 41 trial
Active Trials
NCT02734628Completed28Est. Apr 2007
NCT00859196Completed15Est. Mar 2009
Essential Pharmaceuticals
2 programs
1
1
Electro-thermo-coagulationPhase 2/31 trial
Electro-thermo-coagulationPhase 21 trial
Active Trials
NCT00996463Completed63Est. Mar 2011
NCT00947362Completed134Est. Dec 2007
Vomaris Innovations
2 programs
2
Procellera™ Antimicrobial Wound DressingPhase 21 trial
Procellera™ Wound Dressing with V.A.C.® TherapyPhase 21 trial
Active Trials
NCT01004055Completed15Est. Oct 2009
NCT01022216Completed30Est. Nov 2011
Symbio Pharmaceuticals
1 program
1
TolaSure Topical GelPhase 21 trial
Active Trials
NCT04088357Completed72Est. Apr 2020
ViiV Healthcare
ViiV HealthcareNC - Durham
2 programs
1
GSK1278863Phase 1
0.13% Benzalkonium ChlorideN/A
Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
1 program
1
LUT017Phase 11 trial
Active Trials
NCT07463378Not Yet Recruiting9Est. Feb 2027
ConvaTec
ConvaTecNJ - Bridgewater
2 programs
EDX110 wound dressing systemN/A1 trial
Postop DressingN/A1 trial
Active Trials
NCT06640985Active Not Recruiting43Est. Feb 2026
NCT01258270Completed300Est. May 2013
GSK
GSKLONDON, United Kingdom
1 program
0.13% Benzalkonium ChlorideN/A1 trial
Active Trials
NCT01762982Completed36Est. Feb 2012
Carbon Biosciences
Carbon BiosciencesMA - Waltham
1 program
Acticoat AbsorbentN/A
Biocorp
BiocorpFrance - Issoire
1 program
Acticoat AbsorbentN/A1 trial
Active Trials
NCT01769144Unknown70Est. Apr 2014
Solventum
SolventumMN - St. Paul
1 program
Investigational device: V.A.C. VERAFLO™ Dressing KitN/A1 trial
Active Trials
NCT05902793Completed170Est. Sep 2023
Stryker
StrykerCA - San Jose
1 program
Lower Extremity AmputationN/A1 trial
Active Trials
NCT02440295Completed18Est. Dec 2016
Maruho
MaruhoJapan - Osaka
1 program
Observation of wound healingN/A1 trial
Active Trials
NCT03433820Completed18Est. Mar 2018
Human BioSciences
Human BioSciencesWV - Martinsburg
1 program
Observation of wound healingN/A
Stratpharma
StratpharmaSwitzerland - Basel
1 program
StratacelN/ACell Therapy1 trial
Active Trials
NCT05614557Completed20Est. Aug 2023
Heidelberg Pharma
Heidelberg PharmaGermany - Ladenburg
1 program
Electro-thermo-coagulationPHASE_2

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
BayerDexpanthenol
BayerDexpanthenol
Essential PharmaceuticalsElectro-thermo-coagulation
Symbio PharmaceuticalsTolaSure Topical Gel
Essential PharmaceuticalsElectro-thermo-coagulation
Vomaris InnovationsProcellera™ Wound Dressing with V.A.C.® Therapy
Vomaris InnovationsProcellera™ Antimicrobial Wound Dressing
Angeles TherapeuticsLUT017
ConvaTecEDX110 wound dressing system
StratpharmaStratacel
SolventumInvestigational device: V.A.C. VERAFLO™ Dressing Kit
MaruhoObservation of wound healing
StrykerLower Extremity Amputation
BiocorpActicoat Absorbent
GSK0.13% Benzalkonium Chloride

Showing 15 of 16 trials with date data

Clinical Trials (16)

Total enrollment: 1,041 patients across 16 trials

NCT00859196BayerDexpanthenol

Study to Assess on a Molecular Level the Influence of a 5 % Dexpanthenol Ointment in Subjects With Superficial Injuries

Start: Feb 2009Est. completion: Mar 200915 patients
Phase 4Completed
NCT02734628BayerDexpanthenol

Pilot Study to Assess Number of Patients for Main Trial

Start: Mar 2007Est. completion: Apr 200728 patients
Phase 4Completed
NCT00947362Essential PharmaceuticalsElectro-thermo-coagulation

Rationale for New Topical Anthroponotic Cutaneous Leishmaniasis (ACL) Treatment in Kabul

Start: Aug 2004Est. completion: Dec 2007134 patients
Phase 2/3Completed

Efficacy of Topical TolaSure on Acute Induced Wounds in Healthy Participants

Start: Aug 2019Est. completion: Apr 202072 patients
Phase 2Completed
NCT00996463Essential PharmaceuticalsElectro-thermo-coagulation

Rationales for Wound Care Management in Old World Cutaneous Leishmaniasis Patients

Start: Jan 2010Est. completion: Mar 201163 patients
Phase 2Completed
NCT01022216Vomaris InnovationsProcellera™ Wound Dressing with V.A.C.® Therapy

Efficacy Study of a Bioelectric Dressing Used With Negative Pressure Wound Therapy to Treat Diabetic and Pressure Ulcers

Start: Aug 2009Est. completion: Nov 201130 patients
Phase 2Completed
NCT01004055Vomaris InnovationsProcellera™ Antimicrobial Wound Dressing

Efficacy Study of a Bioelectric Dressing to Treat Wounds Caused by Curettage and Electrodesiccation

Start: Jul 2008Est. completion: Oct 200915 patients
Phase 2Completed

Study of LUT017 Gel to Improve Healing of Skin Wounds After Removal of Benign Lesions in Healthy Adults

Start: Apr 2026Est. completion: Feb 20279 patients
Phase 1Not Yet Recruiting
NCT06640985ConvaTecEDX110 wound dressing system

EDX110 - Efficacy and Safety in the Management of Hard-to-heal Wounds

Start: Dec 2024Est. completion: Feb 202643 patients
N/AActive Not Recruiting

Impact of Silicon-based Formulations on Wound Healing of Laser-induced Microscopic Skin Lesions

Start: Mar 2023Est. completion: Aug 202320 patients
N/ACompleted
NCT05902793SolventumInvestigational device: V.A.C. VERAFLO™ Dressing Kit

Evaluating the Efficacy and Safety of the VERAFLO™ Dressing Kit for Wound Bed Preparation in Open Wounds

Start: Aug 2020Est. completion: Sep 2023170 patients
N/ACompleted
NCT03433820MaruhoObservation of wound healing

Wound Healing in Healthy Volunteers

Start: Oct 2017Est. completion: Mar 201818 patients
N/ACompleted
NCT02440295StrykerLower Extremity Amputation

Pilot Study to Assess the Use of Spy Elite for Assessment of Amputation Healing

Start: May 2015Est. completion: Dec 201618 patients
N/ACompleted
NCT01769144BiocorpActicoat Absorbent

Acticoat Absorbent and BCT Antimicrobial for STSG Donor Site on Thigh

Start: Jan 2013Est. completion: Apr 201470 patients
N/AUnknown
NCT01762982GSK0.13% Benzalkonium Chloride

Patch Test of Benzalkonium Chloride Disinfectant Spray

Start: Feb 2012Est. completion: Feb 201236 patients
N/ACompleted
NCT01258270ConvaTecPostop Dressing

Efficacy and Patient Satisfaction With AQUACEL® Ag Surgical Dressing Compared to Standard Surgical Dressing

Start: Dec 2010Est. completion: May 2013300 patients
N/ACompleted

Related Jobs in Dermatology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

16 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.